Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

Autor: Aki Okamoto, Toshio Naito, Hironobu Sanada, Hirohide Yokokawa
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Blood Glucose
Male
endocrine system diseases
medicine.medical_treatment
Ketone Bodies
030204 cardiovascular system & hematology
chemistry.chemical_compound
0302 clinical medicine
Glucosides
Adipocytes
Medicine
Insulin
Original Research Article
Dapagliflozin
digestive
oral
and skin physiology
Middle Aged
Metformin
C-Reactive Protein
Creatinine
Ketone bodies
Drug Therapy
Combination
Adiponectin
medicine.drug
Adult
medicine.medical_specialty
030209 endocrinology & metabolism
Glucagon
Glucagon-Like Peptide-1 Receptor
03 medical and health sciences
Internal medicine
Diabetes mellitus
Plasminogen Activator Inhibitor 1
Humans
Hypoglycemic Agents
Benzhydryl Compounds
Pharmacology
Glycated Hemoglobin
business.industry
Body Weight
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
medicine.disease
Endocrinology
chemistry
Diabetes Mellitus
Type 2
business
Biomarkers
Zdroj: Drugs in R&D
ISSN: 1179-6901
1174-5886
Popis: Objectives This study aimed to investigate changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics after a meal tolerance test (MTT) during treatment with dapagliflozin among obese type 2 diabetes mellitus (T2DM) patients. Methods T2DM patients with hemoglobin A1c (HbA1c) levels >6.5 % and body mass index (BMI) >25 kg/m2 were treated with dapagliflozin 5 mg/day for at least 12 weeks. HbA1c, body weight, ketone bodies, adiponectin, plasminogen activator inhibitor-1 (PAI-1), and C-reactive protein (CRP) were measured before and after treatment with dapagliflozin. A subset of patients underwent an MTT. Results Of 27 participating patients (mean age 47.9 years; 17 males), five were drug-naive and 22 were treated with other antidiabetic agents, including insulin and glucagon-like peptide-1 (GLP-1) receptor agonists. Following treatment with dapagliflozin, HbA1c levels significantly improved (7.44 ± 0.56 to 6.70 ± 0.0.57 %; p
Databáze: OpenAIRE
Externí odkaz: